Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FT751
- Development stage
- Phase 1
- Lead developer
- Forward Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
FT751 appears to be a research/development code name rather than an approved or widely profiled therapeutic product. Publicly available clinical trial registries, major drug databases, and company pipelines do not provide confirmed details on its mechanism, indication, developer, or development status. The code “FT” is used by Fate Therapeutics for iPSC-derived cell therapies (for example FT516 and FT538), but there is no authoritative public record linking FT751 to a specific mechanism, modality, or sponsor. Given the lack of verifiable information, FT751 should be treated as an unverifiable code name at this time.
Beyond the preview
Go deeper on FT751.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FT751.